SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 3, 2006
SIGMA-ALDRICH CORPORATION
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-8135 | 43-1050617 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
3050 Spruce Street
St. Louis, Missouri 63103
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (314) 771-5765
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.01 Completion of Acquisition or Disposition of Assets.
On May 3, 2006 Sigma-Aldrich issued a press release announcing its acquisition of Honeywell International’s Iropharm unit, a custom chemical synthesis business located in Arklow, Ireland. The addition of Iropharm will substantially increase the Company’s active pharmaceutical ingredient and pharmaceutical intermediates manufacturing capacities, enabling the Company to better support drug development from early-stage through commercialization. Terms of the proposed purchase were not material to the Company. This press release is furnished as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure.
On May 3, 2006 Sigma-Aldrich issued a press release announcing its acquisition of Honeywell International’s Iropharm unit, a custom chemical synthesis business located in Arklow, Ireland. This press release is furnished as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following Exhibits are filed with this Current Report on From 8-K:
| Exhibit Number | Description | |
| 99.1 | Press Release issued May 3, 2006 - SIGMA-ALDRICH ACQUIRES IROPHARM TO EXPAND cGMP CAPACITY. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 4, 2006
| SIGMA-ALDRICH CORPORATION | ||
| By: | /s/ Karen Miller | |
| Karen Miller, Corporate Controller | ||
3
EXHIBIT INDEX
| Exhibit Number | Description | |
| 99.1 | Press Release issued May 3, 2006 - SIGMA-ALDRICH ACQUIRES IROPHARM TO EXPAND cGMP CAPACITY. |
4